Molecular Partners (NASDAQ:MOLN) versus Jade Biosciences (NASDAQ:JBIO) Financial Analysis

Jade Biosciences (NASDAQ:JBIO) and Molecular Partners (NASDAQ:MOLN) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their valuation, profitability, institutional ownership, analyst recommendations, risk, earnings and dividends.

Risk & Volatility

Jade Biosciences has a beta of 1.43, suggesting that its stock price is 43% more volatile than the S&P 500. Comparatively, Molecular Partners has a beta of 1.08, suggesting that its stock price is 8% more volatile than the S&P 500.

Institutional and Insider Ownership

26.6% of Molecular Partners shares are held by institutional investors. 23.1% of Jade Biosciences shares are held by company insiders. Comparatively, 5.9% of Molecular Partners shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Profitability

This table compares Jade Biosciences and Molecular Partners’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Jade Biosciences	N/A	-51.34%	-47.32%
Molecular Partners	N/A	-66.62%	-54.85%

Analyst Recommendations

This is a summary of recent ratings and recommmendations for Jade Biosciences and Molecular Partners, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Jade Biosciences	1	1	6	2	2.90
Molecular Partners	1	1	2	0	2.25

Jade Biosciences currently has a consensus price target of $47.12, indicating a potential upside of 116.07%. Molecular Partners has a consensus price target of $8.38, indicating a potential upside of 113.10%. Given Jade Biosciences’ stronger consensus rating and higher probable upside, research analysts clearly believe Jade Biosciences is more favorable than Molecular Partners.

Earnings & Valuation

This table compares Jade Biosciences and Molecular Partners”s gross revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Jade Biosciences	N/A	N/A	-$127.41 million	($2.02)	-10.80
Molecular Partners	$5.65 million	28.09	-$74.41 million	($1.94)	-2.03

Molecular Partners has higher revenue and earnings than Jade Biosciences. Jade Biosciences is trading at a lower price-to-earnings ratio than Molecular Partners, indicating that it is currently the more affordable of the two stocks.

Summary

Jade Biosciences beats Molecular Partners on 8 of the 13 factors compared between the two stocks.

About Jade Biosciences

Aerovate Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of drugs that enhance the lives of patients with rare cardiopulmonary diseases in the United States. The company focuses on advancing AV-101, a dry powder inhaled formulation of imatinib for the treatment of pulmonary arterial hypertension, which is in Phase 2b/Phase 3 trial. Aerovate Therapeutics, Inc. was incorporated in 2018 and is headquartered in Waltham, Massachusetts.

About Molecular Partners

Molecular Partners AG, a clinical-stage biotechnology company, develops designed ankyrin repeat proteins therapeutics for the treatment of oncology and virology diseases in Switzerland. The company develops MP0317, a CD40 agonist designed to activate immune cells within the tumor microenvironment by anchoring to fibroblast activation protein that is in Phase I clinical trial; and MP0533, a novel tetra-specific T cell-engaging DARPin for acute myeloid leukemia. It also develops Switch-DARPin platform, a multispecific cKIT x CD16a x CD47 Switch-DARPin program for targeted and conditional immune cell activation; and Radio-DARPin Therapy (RDT) platform, a delivery system for effective and selective delivery of radioactive payloads to solid tumors. It has license and research collaboration agreements with Novartis Pharma AG to develop DARPin-conjugated radioligand therapies; and collaboration agreement with Orano Med SAS to develop novel Radio-DARPin therapeutics. Molecular Partners AG was incorporated in 2004 and is headquartered in Schlieren, Switzerland.